Rhea-AI Summary
Jounce Therapeutics reported its Q1 2020 results, ending with $148.6 million in cash. The COVID-19 pandemic impacted the enrollment of the EMERGE Phase 2 trial and initiation of the SELECT trial, causing delays of 2 to 3 months. Interim analysis of the EMERGE trial is now expected in early 2021. Jounce announced CCR8 as the JTX-1811 target, with preclinical data to be presented at AACR 2020 in June. Operating expenses are projected to be $80 to $95 million for the year, but the company expects sufficient cash to meet its needs through 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags